A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States.
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs Alemtuzumab (Primary) ; Busulfan (Primary) ; Melphalan (Primary)
- Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Paroxysmal nocturnal haemoglobinuria; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2013 Planned End Date changed from 1 Feb 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov.